ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : -26 مورد

Factitious hypoglycemia

Factitious hypoglycemia
Author:
Adrian Vella, MD
Section Editor:
Irl B Hirsch, MD
Deputy Editor:
Katya Rubinow, MD
Literature review current through: Apr 2025. | This topic last updated: Jul 29, 2024.

INTRODUCTION — 

Factitious hypoglycemia results from the surreptitious or accidental use of insulin or oral insulin secretagogues (sulfonylureas, meglitinides). The term factitious (or factitial) hypoglycemia is often used to imply covert human activity. Thus, considering this possibility can affect the patient-clinician relationship, leading the clinician to feel deceived and the patient to feel mistrusted. However, the pejorative connotation of factitious hypoglycemia is unwarranted as it does not solely result from covert actions. For example, dispensing errors in the outpatient or inpatient setting can lead to inappropriate administration of hypoglycemic agents. Factitious hypoglycemia therefore should be considered in the differential diagnosis for anyone presenting with unexplained hypoglycemia, and the possibility of factitious hypoglycemia can be evaluated without judgement or accusation.

The clinical features, diagnosis, and treatment of factitious hypoglycemia will be reviewed here. Other causes of hypoglycemia are discussed elsewhere. (See "Hypoglycemia in adults without diabetes mellitus: Clinical manifestations, causes, and diagnosis" and "Insulinoma".)

ETIOLOGY

Causal agents — Factitious hypoglycemia results from the nonprescribed use of insulin or oral insulin secretagogues (sulfonylurea, meglitinides) but generally not from the use of metformin or other drugs used for diabetes management that are not associated with hypoglycemia [1-3].

Glucose-lowering medications that are not insulin secretagogues, such as the thiazolidinediones, alpha-glucosidase inhibitors, and sodium-glucose cotransporter 2 (SGLT2) inhibitors, are generally not associated with hypoglycemia unless they are used in conjunction with insulin or an insulin secretagogue [4,5]. Glucagon-like peptide 1 (GLP-1) receptor agonists stimulate insulin secretion in a glucose-dependent fashion, and their effects on secretion are attenuated as glucose levels decrease. Nonetheless, these agents have been associated with hypoglycemia in patients both with and without underlying diabetes [6] and therefore may complicate the diagnostic evaluation of factitious hypoglycemia. Hypoglycemia has been reported with either accidental or purposeful overdose of the GLP-1 receptor agonist liraglutide, although marked gastrointestinal symptoms appear to be much more prominent than hypoglycemia after GLP-1 receptor agonist overdose [7-9].

Covert administration — Factitious hypoglycemia may be caused by covert self-administration of insulin or oral insulin secretagogues [3] or administration by someone else. Covert self-administration of these agents is considered a form of factitious disorder [10] and includes inappropriate medication use by an individual with diabetes. (See "Factitious disorder imposed on self (Munchausen syndrome)".)

Hypoglycemia also may result from covert administration of insulin or insulin secretagogues to a patient by caregivers, including health care providers. Administration of a hypoglycemic agent by a caregiver to a child is an insidious form of child abuse [11,12]. (See "Medical child abuse (Munchausen syndrome by proxy)".)

The first reported case of factitious hypoglycemia related to a sulfonylurea was due to the surreptitious self-administration of chlorpropamide by a patient without diabetes [13]. Covert insulin administration has also been used in attempted suicide [14]. A review of published cases found that completed suicide occurred in 17 of 97 attempts [15]. In most cases, those attempting suicide were patients with insulin-treated diabetes.

Accidental administration — Accidental ingestion of oral insulin secretagogues may occur due to errors in drug dispensing or administration. It also may occur due to use of contaminated herbal products or medications.

●Dispensing errors – In contrast to patients who knowingly take insulin secretagogues, some patients develop hypoglycemia because a sulfonylurea was mistakenly dispensed [16]. In most instances, confusion in dispensing the drug arises from similarity in spelling between the intended medication and the sulfonylurea. The most common errors in early reports were the substitutions of Diabinese for Diamox [17,18] and of Tolinase for Tolectin; however, Diabinese (chlorpropamide) and Tolinase (tolazamide) are now rarely used [19].

Thus, as part of the initial evaluation for unexplained hypoglycemia, patients should present the containers for all their current prescription and nonprescription medications and supplements. (See 'Initial evaluation' below.)

●Administration errors – Hypoglycemia in an older person whose spouse (or other household member) is treated with an oral insulin secretagogue agent is often due to a mix-up in medication administration. A medical history of the spouse/partner therefore may be an important part of the initial evaluation, as are questions about how medication is prepared for dosing (eg, use of similar versus distinct pill boxes). (See 'Initial evaluation' below.)

●Herbal products or medication contamination – Hypoglycemia also may occur after ingestion of herbal products used to treat diabetes [20] or other conditions [21,22] if contaminated with sulfonylureas. As an example, hypoglycemia has been reported after ingestion of illegal sexual enhancement drugs or herbal preparations contaminated with glyburide in amounts ranging from 13 to 100 mg per tablet [21]. In a case series from Singapore, seven patients who ingested such products were comatose secondary to prolonged neuroglycopenia and four patients subsequently died [21,23].

CLINICAL CHARACTERISTICS

Sociodemographic characteristics — In older reports, factitious hypoglycemia due to covert medication administration was more common in women than men, and it occurred more often in people with health-related occupations and typically during the third or fourth decade of life [3,24,25]. These sociodemographic patterns also have been identified with factitious disorder in general, although not all studies have produced consistent findings. For example, in a case series of individuals who attempted suicide with insulin overdose, the sex distribution was equal and a wide age distribution was evident, ranging from 20 to 70 years [15]. Risk factors for factitious disorder are discussed separately. (See "Factitious disorder imposed on self (Munchausen syndrome)", section on 'Risk factors'.)

Patients without diabetes — Patients without diabetes who have factitious hypoglycemia may present with a clinical syndrome that appears similar to insulinoma; as a result, many may inappropriately undergo surgical exploration or subtotal pancreatectomy. Careful diagnostic evaluation is therefore critical before further studies or procedures are undertaken for presumed insulinoma. (See 'Diagnostic evaluation' below and "Hypoglycemia in adults without diabetes mellitus: Clinical manifestations, causes, and diagnosis", section on 'Clinical manifestations'.)

Patients with diabetes — Factitious hypoglycemia in patients with diabetes is probably more common than the incidence noted in published series [24,26-29]. In patients with factitious hypoglycemia, errors in insulin management can be difficult to distinguish from purposeful manipulation of insulin dosing. Individuals with factitious hypoglycemia typically have repeated episodes of hypoglycemia despite a reduction in insulin dose or even cessation of insulin therapy. When truly deprived of access to hypoglycemic agents, patients with diabetes and factitious hypoglycemia develop hyperglycemia. (See "Hypoglycemia in adults with diabetes mellitus", section on 'Strategies to manage hypoglycemia'.)

Alternatively, patients with diabetes and factitious hypoglycemia may appear to have brittle diabetes [30], with seemingly unexplained, large fluctuations in glycemia. As in individuals without diabetes, factitious hypoglycemia occasionally has been mistaken for insulinoma in people with diabetes, and some patients have undergone needless pancreatic exploration and resection [31,32]. (See 'Differentiating factitious hypoglycemia from other etiologies' below.)

DIAGNOSTIC EVALUATION

When to consider the diagnosis — The possibility of factitious hypoglycemia should be considered in every patient undergoing evaluation for a hypoglycemic disorder. Clinical suspicion is particularly warranted when the individual has access to insulin or oral insulin secretagogues or when the hypoglycemia occurs randomly, without any relation to meals or fasting. Factitious hypoglycemia should be suspected in people with a prior diagnosis of diabetes who have experienced diabetes remission (eg, due to body weight loss) and subsequently develop hypoglycemia.

Factitious hypoglycemia is not uncommon in individuals who present with an apparent hypoglycemic disorder. For example, in a population-based study of unexplained hypoglycemia in France, 7 (5 women, 2 men) of 56 patients had a detectable sulfonylurea in their plasma [33]. The evaluation to establish the presence of a hypoglycemic disorder is reviewed in detail separately. (See "Hypoglycemia in adults without diabetes mellitus: Clinical manifestations, causes, and diagnosis", section on 'Diagnostic evaluation'.)

Initial evaluation — The initial evaluation should include careful review of the patient's clinical and medication history.

●Clinical history – A complete medical history should be obtained for all individuals undergoing evaluation for a hypoglycemic disorder. Factitious hypoglycemia is more likely in individuals who are overall healthy, whereas those with comorbid conditions have a broader differential for potential causes of hypoglycemia.

A key element of the social history is whether the person or any household or family members are health care professionals and therefore could have access to medications that can cause hypoglycemia. A detailed approach to the initial etiologic evaluation of hypoglycemic disorders is presented separately. (See "Hypoglycemia in adults without diabetes mellitus: Determining the etiology", section on 'Initial assessment to determine the etiology'.)

●Medication history – All medications, including herbal preparations or other over-the-counter products, should be identified. The assistance of a pharmacist is often helpful. Patients should bring in all medication containers for visual inspection and provide a detailed account of how each medication is administered; these steps can help identify possible dispensing or administration errors.

A complete medication list for all household members also should be obtained, as this information can reveal access to insulin or insulin secretagogues. It also can help identify potential medication administration errors (eg, accidental ingestion of a household member's medication).

Non-glucose-lowering medications that can cause hypoglycemia are discussed separately (table 1). (See "Hypoglycemia in adults without diabetes mellitus: Clinical manifestations, causes, and diagnosis", section on 'Medications and alcohol'.)

Laboratory evaluation

Biochemical tests — Most of the key diagnostic laboratory tests should be obtained during an episode of hypoglycemia. In contrast, anti-insulin antibodies can be measured at any time.

●Tests during hypoglycemia – The diagnosis of factitious hypoglycemia usually can be established by documenting the presence of hypoglycemia and by simultaneously measuring plasma levels of the following:

•Insulin

•C-peptide

•Proinsulin

•Insulin secretagogues (sulfonylurea and meglitinides)

For most individuals, this evaluation may be performed either during a spontaneous episode of hypoglycemia or through supervised testing (algorithm 1). Performance of a 72-hour fast, which is primarily used to diagnose insulinoma, may be required in patients with factitious hypoglycemia. Nonetheless, the fast may be negative if the patient does not take the offending agent.

In patients with diabetes who are treated with oral insulin secretagogues or insulin (including inhaled insulin), confirmation of factitious hypoglycemia can be very difficult. Diagnosis requires an assessment under controlled conditions, where individuals can be closely monitored and observed, with all blood glucose testing, food, and insulin administered by the staff. (See "Hypoglycemia in adults without diabetes mellitus: Determining the etiology", section on 'Supervised testing'.)

●Anti-insulin antibodies – Anti-insulin antibodies should be measured in all patients with insulin-treated diabetes and in patients not treated with insulin who have biochemical evidence of insulin-mediated hypoglycemia.

•Patients on insulin therapy – In all patients with insulin-treated diabetes, insulin antibodies should be measured once, but they do not have to be measured during an episode of hypoglycemia. The detection of anti-insulin antibodies in insulin-treated patients has no diagnostic utility because the presence of such antibodies is common. However, the presence of anti-insulin antibodies can interfere with measurements of plasma insulin and C-peptide concentrations. As a result, if anti-insulin antibodies are present, free insulin and C-peptide levels should be measured when possible. The titers of anti-insulin antibodies have fallen over time with the use of human insulin formulations and insulin analogs compared with the earlier use of animal source insulins [34].

•Patients not taking insulin therapy – In patients who are not treated with insulin, anti-insulin antibodies should be measured only if the laboratory evaluation suggests hypoglycemia due to endogenous hyperinsulinism (algorithm 2). Antibodies do not have to be measured during an episode of hypoglycemia. In this setting, the presence of anti-insulin antibodies helps evaluate for possible autoimmune hypoglycemia. In autoimmune hypoglycemia, insulin antibodies are spontaneously generated without prior exposure to exogenous insulin [35,36]. Patients with autoimmune hypoglycemia have high plasma titers of insulin antibodies and may have a history of autoimmune disease or exposure to sulfhydryl-containing drugs. (See "Hypoglycemia in adults without diabetes mellitus: Determining the etiology", section on 'C-peptide level ≥0.2 nmol/L'.)

Differentiating factitious hypoglycemia from other etiologies — The approach to interpreting laboratory test results during a supervised fast is shown in the algorithms and reviewed in detail elsewhere (algorithm 2 and algorithm 3). (See "Hypoglycemia in adults without diabetes mellitus: Determining the etiology", section on 'Interpretation of supervised fast results'.)

In patients with hyperinsulinemic hypoglycemia, the distinction between an endogenous or exogenous source of insulin can be made by measuring plasma C-peptide and insulin at the time of the hypoglycemic episode (and preferably in the same sample) (table 2 and algorithm 2) [37]. Interpretation of C-peptide, insulin, and glucose levels must be performed in concert; none of these tests is diagnostically useful in isolation. Key findings that differentiate factitious hypoglycemia from other etiologies of hypoglycemia depend on whether hypoglycemia appears due to endogenous or exogenous hyperinsulinism.

●Hypoglycemia due to endogenous hyperinsulinism – Factitious hypoglycemia caused by insulin secretagogues (sulfonylureas or glucagon-like peptide 1 [GLP-1] receptor agonists) biochemically mimics insulinoma. Insulin and C-peptide are secreted in an equimolar fashion [38]; as a result, the plasma concentrations of these two peptides parallel each other in patients with endogenous hyperinsulinism. Patients with insulinoma, autoimmune hypoglycemia, or insulin secretagogue-induced hypoglycemia can have plasma insulin, C-peptide, and proinsulin values above or within the fasting reference range during confirmed hypoglycemia. (Values within the reference range are abnormal if the plasma glucose concentration is low.) The detection of sulfonylureas or meglitinides in the plasma or urine confirms the diagnosis of factitious hypoglycemia (table 2 and algorithm 2) [35,39].

In autoimmune hypoglycemia, both the plasma insulin and C-peptide concentrations can be very high, with plasma insulin levels often well above 1000 microU/mL (6000 pmol/L). The diagnosis is confirmed through detection of anti-insulin antibodies. Antibodies do not have to be measured during an episode of hypoglycemia. (See 'Biochemical tests' above and "Hypoglycemia in adults without diabetes mellitus: Determining the etiology", section on 'C-peptide level ≥0.2 nmol/L'.)

●Hypoglycemia due to exogenous hyperinsulinism – In contrast, in patients with factitious hypoglycemia due to insulin use, plasma insulin values are typically high (often above 100 microU/mL [600 pmol/L]), whereas plasma C-peptide and proinsulin values are suppressed, usually close to the lower limit of detection for the assay (table 2 and algorithm 2). This observation applies to both patients without diabetes [24,40,41] and to those with type 2 diabetes [24,26,29]. Patients with type 1 diabetes are characteristically severely insulin deficient and have low or undetectable plasma concentrations of C-peptide. Although the C-peptide values in these patients cannot be further suppressed, confirmation that C-peptide is low during hypoglycemia eliminates any consideration of endogenous hyperinsulinism (ie, due to insulinoma) [28,42].

However, in hypoglycemia caused by synthetic insulin analogs (eg, glargine, lispro, aspart), insulin concentrations may be low, depending upon the insulin assay used. Clinical suspicion should guide subsequent testing for various insulin analogs. For example, suppressed ketogenesis despite an appropriately low insulin level may suggest the presence of an unmeasured insulin analog. The same sample obtained at the time of hypoglycemia should be used for such additional testing. (See 'Type of insulin assay' below and "Hypoglycemia in adults without diabetes mellitus: Determining the etiology", section on 'Interpretation of supervised fast results'.)

Caveats for interpretation — Misinterpretation of laboratory test results can lead to misdiagnosis of either insulinoma or factitious hypoglycemia. Misdiagnosis can deprive the patient of a potentially curative procedure (if the diagnosis of insulinoma is missed) [43], lead to unnecessary surgery (if the diagnosis of insulin secretagogue use is missed), or result in subsequent, potentially fatal hypoglycemic events. Thus, thoughtful selection of laboratory assays and careful interpretation of test results are critical (algorithm 2 and algorithm 3).

Type of insulin assay — Some insulin assays detect only human insulin, whereas others detect both human insulin and synthetic insulin analogs (glargine, detemir, lispro, aspart) [44-46]. In addition, some assays have been developed to specifically measure synthetic insulin analogs (eg, lispro, aspart) or animal insulin (porcine, beef) without any cross-reactivity with human insulin [47-49]. Assay specificity depends upon the selection of monoclonal antibody used for detection. Mass spectrometry-based assays allow rapid identification of human insulin and its synthetic or animal analogs [50-52]. It is important for the clinician to know which insulin assay is used and whether it measures human insulin, insulin analogs, or both. This helps determine whether additional testing with different assays is indicated.

Insulin secretagogue detection — During confirmed hypoglycemia, plasma should be obtained for the measurement of sulfonylureas and meglitinides (nateglinide, repaglinide). It is important to verify that the assay used can reliably identify all these compounds. The Department of Laboratory Medicine at the Mayo Clinic developed a liquid chromatography-tandem mass spectrometry (LC-MS/MS) method that is highly sensitive for the detection of sulfonylureas and meglitinides. Similar assays are available in other countries [53,54]. Capillary electrophoresis (CE) and high-performance liquid chromatography (HPLC) assays are also available for detecting surreptitious use of sulfonylureas or meglitinides [55,56].

MANAGEMENT

Acute reversal of hypoglycemia — The acute management of factitious hypoglycemia is generally similar to the management of hypoglycemia during the treatment of diabetes. The treatment of hypoglycemia in individuals with diabetes is reviewed in more detail elsewhere. (See "Hypoglycemia in adults with diabetes mellitus", section on 'Reversing hypoglycemia'.)

●Symptomatic hypoglycemia – Patients with symptomatic hypoglycemia should ingest carbohydrates (eg, 15 to 20 grams of oral glucose). Glucose may be ingested in the form of glucose tablets, juice, milk, or other snacks. Rapid absorption of the carbohydrate is key, so fat-rich foods (eg, ice cream) or full meals, which may delay carbohydrate absorption, are not recommended for acute management.

●Severe hypoglycemia – Severe hypoglycemia is defined as hypoglycemia that impairs cognition sufficiently to require assistance from another person [57].

•Outpatient setting – Treatment of severe hypoglycemia, when the patient is unconscious or unable to ingest carbohydrate, requires glucagon administration. Glucagon (0.5 to 1 mg) can be administered intranasally or by subcutaneous or intramuscular injection.

•Inpatient setting – Patients brought to the hospital can be treated more quickly by giving 25 g of 50 percent glucose (dextrose) intravenously (IV). A subsequent glucose infusion (or food, if patient is able to eat) is often needed, depending upon the half-life of the drug causing the hypoglycemia.

●Refractory or recurrent hypoglycemia – Refractory or recurrent hypoglycemia may evolve after ingestion of sulfonylureas with longer duration of action. In this setting, octreotide may be used, although data supporting its use are limited. As an example, in a trial of adults with sulfonylurea-induced hypoglycemia, participants who were randomly assigned to receive octreotide (a single subcutaneous dose of 75 mcg) in addition to 1 ampule of 50 percent dextrose IV had significantly higher mean glucose values during the first eight hours of therapy than those who received only IV dextrose [58]. (See "Sulfonylurea agent poisoning", section on 'Intoxication'.)

●Intentional sulfonylurea overdose – In the setting of symptomatic hypoglycemia due to sulfonylurea overdose, octreotide should be administered. Management of sulfonylurea overdose is reviewed in detail separately. (See "Sulfonylurea agent poisoning", section on 'Symptomatic intentional overdose'.)

Long-term management — The long-term treatment of factitious hypoglycemia involves changing behavioral patterns to protect the patient from the consequences of hypoglycemia. Meetings held to inform patients about their diagnosis may be more effective when they are a collaborative intervention by an attending clinician and mental health specialist together. Having the support of caregivers/family members is also important for mediating behavioral change. It is important to emphasize that the patient needs help, providing assurance that medical care and support are available. (See "Factitious disorder imposed on self (Munchausen syndrome)", section on 'Specific treatment' and "Factitious disorder imposed on self (Munchausen syndrome)", section on 'Prognosis'.)

SOCIETY GUIDELINE LINKS — 

Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See "Society guideline links: Hypoglycemia in adults".)

INFORMATION FOR PATIENTS — 

UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5th to 6th grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10th to 12th grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.

Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)

●Basics topic (see "Patient education: Low blood sugar in people without diabetes (The Basics)")

SUMMARY AND RECOMMENDATIONS

●Etiology – Factitious hypoglycemia results from the use of insulin or insulin secretagogues (sulfonylurea, meglitinides) but not from metformin or other drugs used for diabetes management that are not associated with hypoglycemia. (See 'Etiology' above.)

●Clinical characteristics – Patients without diabetes who have factitious hypoglycemia may present with a clinical syndrome that appears similar to insulinoma. Patients with diabetes and factitious hypoglycemia may have repeated episodes of hypoglycemia despite a reduction in insulin dose or even cessation of insulin therapy. (See 'Clinical characteristics' above and "Hypoglycemia in adults without diabetes mellitus: Clinical manifestations, causes, and diagnosis", section on 'Clinical manifestations'.)

●Diagnostic evaluation

•When to consider – The possibility of factitious hypoglycemia should be considered in every patient undergoing evaluation for a hypoglycemic disorder. Clinical suspicion is particularly warranted when the individual has access to insulin or other glucose-lowering agents or when the hypoglycemia occurs randomly, without any relation to meals or fasting. (See 'When to consider the diagnosis' above.)

•Initial evaluation – A complete clinical and medication history are critical for the initial evaluation. All medications, including herbal preparations or other over-the-counter products, should be identified and visually inspected (table 1). (See 'Initial evaluation' above.)

●Laboratory evaluation

•Biochemical tests – The diagnosis of factitious hypoglycemia can usually be established by documenting the presence of hypoglycemia and by simultaneously measuring plasma levels of the following:

-Insulin

-C-peptide

-Proinsulin

-Insulin secretagogues (sulfonylurea and meglitinides)

For most individuals, this evaluation may be performed either during a spontaneous episode of hypoglycemia or through supervised testing (algorithm 1). (See 'Biochemical tests' above.)

In patients with diabetes who are treated with insulin or oral insulin secretagogues, confirmation of factitious hypoglycemia can be very difficult. Diagnosis requires an assessment under controlled conditions, where individuals can be closely monitored and observed. (See "Hypoglycemia in adults without diabetes mellitus: Determining the etiology", section on 'Supervised testing'.)

•Test interpretation – Patients with insulinoma, autoimmune hypoglycemia, or insulin secretagogue-induced hypoglycemia can have plasma insulin, C-peptide, and proinsulin values above or within the fasting reference range during confirmed hypoglycemia. The detection of sulfonylureas or meglitinides in the plasma confirms the diagnosis of factitious hypoglycemia (table 2 and algorithm 2 and algorithm 3).

In contrast, in patients with factitious hypoglycemia due to insulin use, plasma insulin values are typically high (often above 100 microU/mL [600 pmol/L]), whereas plasma C-peptide and proinsulin values are suppressed, usually close to the lower limit of detection for the assay. However, in hypoglycemia caused by synthetic insulin analogs (eg, glargine, detemir, lispro, aspart), insulin concentrations may be low, depending upon the insulin assay used. Clinical suspicion should guide subsequent testing for various insulin analogs. (See 'Differentiating factitious hypoglycemia from other etiologies' above.)

●Management – The acute management of factitious hypoglycemia is similar to the management of hypoglycemia during the treatment of diabetes. The long-term treatment of factitious hypoglycemia involves changing behavioral patterns. (See 'Management' above and "Hypoglycemia in adults with diabetes mellitus", section on 'Reversing hypoglycemia'.)

ACKNOWLEDGMENT — 

The UpToDate editorial staff acknowledges F John Service, MD, PhD, who contributed to earlier versions of this topic review.

  1. Hirshberg B, Skarulis MC, Pucino F, et al. Repaglinide-induced factitious hypoglycemia. J Clin Endocrinol Metab 2001; 86:475.
  2. Marks V, Teale JD. Hypoglycemia: factitious and felonious. Endocrinol Metab Clin North Am 1999; 28:579.
  3. Oueslati I, Terzi A, Yazidi M, et al. Prevalence and characteristics of factitious hypoglycaemia in non-diabetic patients in a department of endocrinology. Endocrinol Diabetes Metab 2022; 5:e375.
  4. Horii T, Oikawa Y, Kunisada N, et al. Real-world risk of hypoglycemia-related hospitalization in Japanese patients with type 2 diabetes using SGLT2 inhibitors: a nationwide cohort study. BMJ Open Diabetes Res Care 2020; 8.
  5. Nakamura M, Nakade J, Toyama T, et al. Severe intoxication caused by sodium-glucose cotransporter 2 inhibitor overdose: a case report. BMC Pharmacol Toxicol 2020; 21:5.
  6. Zhao Z, Tang Y, Hu Y, et al. Hypoglycemia following the use of glucagon-like peptide-1 receptor agonists: a real-world analysis of post-marketing surveillance data. Ann Transl Med 2021; 9:1482.
  7. Nafisah SB, Almatrafi D, Al-Mulhim K. Liraglutide overdose: A case report and an updated review. Turk J Emerg Med 2020; 20:46.
  8. Wiener BG, Gnirke M, Vassallo S, et al. Challenges with glucagon-like peptide-1 (GLP-1) agonist initiation: a case series of semaglutide overdose administration errors. Clin Toxicol (Phila) 2024; 62:131.
  9. Marshall S, Ryan E, Rivera J, et al. GLP-1 Receptor Agonist Exposures Are Increasingly Common and Generally Associated with Mild Symptoms: A Single Poison Center Experience. J Med Toxicol 2024; 20:278.
  10. Sharifzadeh A. Hypoglycemia and Factitious Disorders: A Case Report and Review. Cureus 2022; 14:e26287.
  11. Giurgea I, Ulinski T, Touati G, et al. Factitious hyperinsulinism leading to pancreatectomy: severe forms of Munchausen syndrome by proxy. Pediatrics 2005; 116:e145.
  12. Given BD, Ostrega DM, Polonsky KS, et al. Hypoglycemia due to surreptitious injection of insulin. Identification of insulin species by high-performance liquid chromatography. Diabetes Care 1991; 14:544.
  13. DUNCAN GG, JENSON W, EBERLY RJ. Factitious hypoglycemia due to chlorpropamide. Report of a case, with clinical similarity to an islet cell tumor of the pancreas. JAMA 1961; 175:904.
  14. Roberge RJ, Martin TG, Delbridge TR. Intentional massive insulin overdose: recognition and management. Ann Emerg Med 1993; 22:228.
  15. Kaminer Y, Robbins DR. Insulin misuse: a review of an overlooked psychiatric problem. Psychosomatics 1989; 30:19.
  16. Klonoff DC, Barrett BJ, Nolte MS, et al. Hypoglycemia following inadvertent and factitious sulfonylurea overdosages. Diabetes Care 1995; 18:563.
  17. Aderka D, Pinkhas J. Inadvertently induced hypoglycemia. JAMA 1978; 240:1140.
  18. Hooper PL, Tello RJ, Burstein PJ, Abrams RS. Pseudoinsulinoma--the Diamox-Diabinese switch. N Engl J Med 1990; 323:488.
  19. Ahlquist DA, Nelson RL, Callaway CW. Pseudoinsulinoma syndrome from inadvertent tolazamide ingestion. Ann Intern Med 1980; 93:281.
  20. Goudie AM, Kaye JM. Contaminated medication precipitating hypoglycaemia. Med J Aust 2001; 175:256.
  21. Kao SL, Chan CL, Tan B, et al. An unusual outbreak of hypoglycemia. N Engl J Med 2009; 360:734.
  22. Dalan R, Leow MK, George J, et al. Neuroglycopenia and adrenergic responses to hypoglycaemia: insights from a local epidemic of serendipitous massive overdose of glibenclamide. Diabet Med 2009; 26:105.
  23. Lim CC, Gan R, Chan CL, et al. Severe hypoglycemia associated with an illegal sexual enhancement product adulterated with glibenclamide: MR imaging findings. Radiology 2009; 250:193.
  24. Grunberger G, Weiner JL, Silverman R, et al. Factitious hypoglycemia due to surreptitious administration of insulin. Diagnosis, treatment, and long-term follow-up. Ann Intern Med 1988; 108:252.
  25. Bhatnagar D. Diagnosis of factitious hypoglycaemia. Br J Hosp Med 1988; 40:140.
  26. Ensberg M, Gossain VV, Rovner DR. Factitious hypoglycemia. Clues to identifying an elusive disorder. Postgrad Med 1986; 79:79.
  27. Dimitriadis G, Raptis S, Zoupas C, Schizas N. The validity of C-peptide measurement in the diagnosis of factitious hypoglycemia. Acta Diabetol Lat 1980; 17:67.
  28. Miccoli R, Marchetti P, Giampietro O, et al. Factitious hypoglycemia in an insulin-dependent woman in the eighth week of gestation. Gynecol Obstet Invest 1986; 21:52.
  29. Toth EL. Factitious hypoglycemia and the multiple personality disorder. Ann Intern Med 1990; 112:76.
  30. Hirsch IB, Gaudiani LM. A new look at brittle diabetes. J Diabetes Complications 2021; 35:107646.
  31. GITTLER RD, ZUCKER G, EISINGER R, STOLLER N. Amelioration of diabetes mellitus by an insulinoma. N Engl J Med 1958; 258:932.
  32. Braithwaite SS, Eatherton JK, Ellos WJ, et al. The ethics of surreptitious diagnostics for factitious hypoglycemia. J Clin Ethics 1990; 1:116.
  33. Trenque T, Frances C, Millart H, et al. Prevalence of factitious hypoglycaemia associated with sulphonylurea drugs in France in the year 2000. Br J Clin Pharmacol 2002; 54:548.
  34. Schernthaner G. Immunogenicity and allergenic potential of animal and human insulins. Diabetes Care 1993; 16 Suppl 3:155.
  35. Klein RF, Seino S, Sanz N, et al. High performance liquid chromatography used to distinguish the autoimmune hypoglycemia syndrome from factitious hypoglycemia. J Clin Endocrinol Metab 1985; 61:571.
  36. Seino S, Fu ZZ, Marks W, et al. Characterization of circulating insulin in insulin autoimmune syndrome. J Clin Endocrinol Metab 1986; 62:64.
  37. Pfützner A, Löbig M, Fortunato A, Forst T. Evaluation of a new fully automated one-step C-peptide chemiluminescence assay (LIAISON C-Peptid). Clin Lab 2003; 49:227.
  38. Rubenstein AH, Block MB, Starr J, et al. Proinsulin and C-peptide in blood. Diabetes 1972; 21:661.
  39. Perros P, Henderson AK, Carter DC, Toft AD. Lesson of the week. Are spontaneous hypoglycaemia, raised plasma insulin and C peptide concentrations, and abnormal pancreatic images enough to diagnose insulinoma? BMJ 1997; 314:496.
  40. Murray BJ. Hypoglycemia secondary to factitious hyperinsulinism. Postgrad Med 1981; 69:237, 240.
  41. Biliotti GC, Vestrini G, Tonelli P, et al. Factitious hypoglycemia: an unusual clinical picture within Von Münchausen's syndrome. Ital J Surg Sci 1983; 13:41.
  42. Service FJ, Rubenstein A, Horwitz DL. C-peptide analysis in diagnosis of factitial hypoglycemia in an insulin-dependent diabetic. Mayo Clin Proc 1975; 50:697.
  43. Service FJ, McMahon MM, O'Brien PC, Ballard DJ. Functioning insulinoma--incidence, recurrence, and long-term survival of patients: a 60-year study. Mayo Clin Proc 1991; 66:711.
  44. Neal JM, Han W. Insulin immunoassays in the detection of insulin analogues in factitious hypoglycemia. Endocr Pract 2008; 14:1006.
  45. Moriyama M, Hayashi N, Ohyabu C, et al. Performance evaluation and cross-reactivity from insulin analogs with the ARCHITECT insulin assay. Clin Chem 2006; 52:1423.
  46. Owen WE, Roberts WL. Cross-reactivity of three recombinant insulin analogs with five commercial insulin immunoassays. Clin Chem 2004; 50:257.
  47. Bowsher RR, Lynch RA, Brown-Augsburger P, et al. Sensitive RIA for the specific determination of insulin lispro. Clin Chem 1999; 45:104.
  48. Andersen L, Jørgensen PN, Jensen LB, Walsh D. A new insulin immunoassay specific for the rapid-acting insulin analog, insulin aspart, suitable for bioavailability, bioequivalence, and pharmacokinetic studies. Clin Biochem 2000; 33:627.
  49. Walfish PG, Feig DS, Bauman WA. Factitious hyperinsulinemic hypoglycemia: confirmation of the diagnosis by a species-specific insulin radioimmunoassay. J Endocrinol Invest 1987; 10:601.
  50. Thomas A, Schänzer W, Thevis M. Determination of human insulin and its analogues in human blood using liquid chromatography coupled to ion mobility mass spectrometry (LC-IM-MS). Drug Test Anal 2014; 6:1125.
  51. Thomas A, Thevis M. Analysis of insulin and insulin analogs from dried blood spots by means of liquid chromatography-high resolution mass spectrometry. Drug Test Anal 2018; 10:1761.
  52. Egan AM, Galior KD, Maus AD, et al. Pitfalls in Diagnosing Hypoglycemia Due to Exogenous Insulin: Validation and Utility of an Insulin Analog Assay. Mayo Clin Proc 2022; 97:1994.
  53. Hoizey G, Lamiable D, Trenque T, et al. Identification and quantification of 8 sulfonylureas with clinical toxicology interest by liquid chromatography-ion-trap tandem mass spectrometry and library searching. Clin Chem 2005; 51:1666.
  54. Wang M, Miksa IR. Multi-component plasma quantitation of anti-hyperglycemic pharmaceutical compounds using liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2007; 856:318.
  55. Paroni R, Comuzzi B, Arcelloni C, et al. Comparison of capillary electrophoresis with HPLC for diagnosis of factitious hypoglycemia. Clin Chem 2000; 46:1773.
  56. Malli D, Gikas E, Vavagiannis A, et al. Determination of nateglinide in human plasma by high-performance liquid chromatography with pre-column derivatization using a coumarin-type fluorescent reagent. Anal Chim Acta 2007; 599:143.
  57. International Hypoglycaemia Study Group. Glucose Concentrations of Less Than 3.0 mmol/L (54 mg/dL) Should Be Reported in Clinical Trials: A Joint Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2017; 40:155.
  58. Fasano CJ, O'Malley G, Dominici P, et al. Comparison of octreotide and standard therapy versus standard therapy alone for the treatment of sulfonylurea-induced hypoglycemia. Ann Emerg Med 2008; 51:400.
Topic 1799 Version 24.0

References

1 : Repaglinide-induced factitious hypoglycemia.

2 : Hypoglycemia: factitious and felonious.

3 : Prevalence and characteristics of factitious hypoglycaemia in non-diabetic patients in a department of endocrinology.

4 : Real-world risk of hypoglycemia-related hospitalization in Japanese patients with type 2 diabetes using SGLT2 inhibitors: a nationwide cohort study.

5 : Severe intoxication caused by sodium-glucose cotransporter 2 inhibitor overdose: a case report.

6 : Hypoglycemia following the use of glucagon-like peptide-1 receptor agonists: a real-world analysis of post-marketing surveillance data.

7 : Liraglutide overdose: A case report and an updated review.

8 : Challenges with glucagon-like peptide-1 (GLP-1) agonist initiation: a case series of semaglutide overdose administration errors.

9 : GLP-1 Receptor Agonist Exposures Are Increasingly Common and Generally Associated with Mild Symptoms: A Single Poison Center Experience.

10 : Hypoglycemia and Factitious Disorders: A Case Report and Review.

11 : Factitious hyperinsulinism leading to pancreatectomy: severe forms of Munchausen syndrome by proxy.

12 : Hypoglycemia due to surreptitious injection of insulin. Identification of insulin species by high-performance liquid chromatography.

13 : Factitious hypoglycemia due to chlorpropamide. Report of a case, with clinical similarity to an islet cell tumor of the pancreas.

14 : Intentional massive insulin overdose: recognition and management.

15 : Insulin misuse: a review of an overlooked psychiatric problem.

16 : Hypoglycemia following inadvertent and factitious sulfonylurea overdosages.

17 : Inadvertently induced hypoglycemia.

18 : Pseudoinsulinoma--the Diamox-Diabinese switch.

19 : Pseudoinsulinoma syndrome from inadvertent tolazamide ingestion.

20 : Contaminated medication precipitating hypoglycaemia.

21 : An unusual outbreak of hypoglycemia.

22 : Neuroglycopenia and adrenergic responses to hypoglycaemia: insights from a local epidemic of serendipitous massive overdose of glibenclamide.

23 : Severe hypoglycemia associated with an illegal sexual enhancement product adulterated with glibenclamide: MR imaging findings.

24 : Factitious hypoglycemia due to surreptitious administration of insulin. Diagnosis, treatment, and long-term follow-up.

25 : Diagnosis of factitious hypoglycaemia.

26 : Factitious hypoglycemia. Clues to identifying an elusive disorder.

27 : The validity of C-peptide measurement in the diagnosis of factitious hypoglycemia.

28 : Factitious hypoglycemia in an insulin-dependent woman in the eighth week of gestation.

29 : Factitious hypoglycemia and the multiple personality disorder.

30 : A new look at brittle diabetes.

31 : Amelioration of diabetes mellitus by an insulinoma.

32 : The ethics of surreptitious diagnostics for factitious hypoglycemia.

33 : Prevalence of factitious hypoglycaemia associated with sulphonylurea drugs in France in the year 2000.

34 : Immunogenicity and allergenic potential of animal and human insulins.

35 : High performance liquid chromatography used to distinguish the autoimmune hypoglycemia syndrome from factitious hypoglycemia.

36 : Characterization of circulating insulin in insulin autoimmune syndrome.

37 : Evaluation of a new fully automated one-step C-peptide chemiluminescence assay (LIAISON C-Peptid).

38 : Proinsulin and C-peptide in blood.

39 : Lesson of the week. Are spontaneous hypoglycaemia, raised plasma insulin and C peptide concentrations, and abnormal pancreatic images enough to diagnose insulinoma?

40 : Hypoglycemia secondary to factitious hyperinsulinism.

41 : Factitious hypoglycemia: an unusual clinical picture within Von Münchausen's syndrome.

42 : C-peptide analysis in diagnosis of factitial hypoglycemia in an insulin-dependent diabetic.

43 : Functioning insulinoma--incidence, recurrence, and long-term survival of patients: a 60-year study.

44 : Insulin immunoassays in the detection of insulin analogues in factitious hypoglycemia.

45 : Performance evaluation and cross-reactivity from insulin analogs with the ARCHITECT insulin assay.

46 : Cross-reactivity of three recombinant insulin analogs with five commercial insulin immunoassays.

47 : Sensitive RIA for the specific determination of insulin lispro.

48 : A new insulin immunoassay specific for the rapid-acting insulin analog, insulin aspart, suitable for bioavailability, bioequivalence, and pharmacokinetic studies.

49 : Factitious hyperinsulinemic hypoglycemia: confirmation of the diagnosis by a species-specific insulin radioimmunoassay.

50 : Determination of human insulin and its analogues in human blood using liquid chromatography coupled to ion mobility mass spectrometry (LC-IM-MS).

51 : Analysis of insulin and insulin analogs from dried blood spots by means of liquid chromatography-high resolution mass spectrometry.

52 : Pitfalls in Diagnosing Hypoglycemia Due to Exogenous Insulin: Validation and Utility of an Insulin Analog Assay.

53 : Identification and quantification of 8 sulfonylureas with clinical toxicology interest by liquid chromatography-ion-trap tandem mass spectrometry and library searching.

54 : Multi-component plasma quantitation of anti-hyperglycemic pharmaceutical compounds using liquid chromatography-tandem mass spectrometry.

55 : Comparison of capillary electrophoresis with HPLC for diagnosis of factitious hypoglycemia.

56 : Determination of nateglinide in human plasma by high-performance liquid chromatography with pre-column derivatization using a coumarin-type fluorescent reagent.

57 : Glucose Concentrations of Less Than 3.0 mmol/L (54 mg/dL) Should Be Reported in Clinical Trials: A Joint Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes.

58 : Comparison of octreotide and standard therapy versus standard therapy alone for the treatment of sulfonylurea-induced hypoglycemia.